Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Intuitive Surgical, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Intuitive Surgical, Inc. trades at $424 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 11.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Intuitive Surgical, Inc. for 84 Days on average.
| HALO | ISRG | |
|---|---|---|
Market Cap | $12.58B | $146.76B |
Volume | 2,179,278 | 2,529,814 |
Sector | Health | Health |
52-Week High | $115.22 | $592.85 |
52-Week Low | $61.63 | $332.02 |
Typical Hold Time | 1 Days | 84 Days |
Enterprise Value | $14.49B | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intuitive Surgical (ISRG) trades at $423.96, up 2.28% with strong bullish momentum. The stock shows robust fundamentals with 2025 revenue reaching $10.06B and net income of $2.86B, maintaining 28.45% net margins. Recent quarters consistently beat EPS estimates, while technical indicators signal bullish moving averages. Analyst consensus remains strongly positive with 70% buy ratings and $480.78 price target, representing 13% upside potential.
ISRG's leadership in robotic surgery and expanding international presence in India and Japan provide growth catalysts, though China weakness and competitive pressures present risks. The stock's premium valuation (P/E 47.64) reflects high growth expectations, requiring continued execution. Current levels near resistance at $427 may test near-term momentum ahead of Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
